Companies · Pharmaceuticals

Edison Oncology Holding Corp

MENLO PARK · Pharmaceuticals

Diligence memoA one-page analyst read on Edison Oncology Holding Corp — recommendation, valuation, rhythm, risks.
$882K
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 83%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Dec 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Edison Oncology Holding Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.66× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.5 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Edison Oncology Holding Corp behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
7.7 yr record
Peak capital year was 2018 with $632K across 1 filings.
Market position
ahead of 18% of Pharmaceuticals peers
Capital scale is ahead of 18% of Pharmaceuticals peers; modeled value is above 15% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2018: $632K across 1 filings.
  • Largest single filing was $632K on 2018-10-05.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Edison Oncology Holding Corp is one of 1613 Pharmaceuticals companies tracked from MENLO PARK. By capital raised it ranks in the long tail (ahead of 18% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
7
Investors (latest)
2018
Year incorporated
2020-12-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2018-10-05 Raised $632K (real) Modeled valuation $30M (est)$632K$30MPre-Seed2018Pre-Seed · 2020-12-30 Raised $250K (real) Modeled valuation $8.8M (est)$250K$8.8MPre-Seed2020+$250KCumulative $882K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$632K · 2018
Pre-Seed extension$250K · 2020

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$8.8M
Base estimate est.
$140K
Conservative case
$86.1M
Upside case
$1.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $29.9M · 2018-10-052018Pre-Seed · modeled $8.8M · 2020-12-302020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
5.5 yr
Elapsed time used
5.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
27 mo
Avg between rounds
$395K/yr
Capital velocity
7.7 yr
On record since
2018
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$882K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.6× of median
This company$250K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$8.8M
Sector median$76.1M

Raised more than 18% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #36 of 46.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Elion Oncology, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Cyclone Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Sonnet Biotherapeutics, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Fastball Capital Group, Llc · Pre-Seed Raised $750K · modeled $35.5M (est)TamRx, LLC · Pre-Seed Raised $700K · modeled $33.1M (est)Veana Therapeutics, Inc. · Pre-Seed Raised $1.4M · modeled $32.9M (est)Ariz Precision Medicine, Inc. · Pre-Seed Raised $685K · modeled $32.4M (est)Vascarta Inc. · Pre-Seed Raised $649K · modeled $28.1M (est)Enfuego Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $27.0M (est)Sincerus Pharmaceuticals Inc · Pre-Seed Raised $506K · modeled $23.9M (est)Neurodon Corp · Pre-Seed Raised $500K · modeled $23.7M (est)Elite Pharmaceuticals Inc /Nv/ · Pre-Seed Raised $3.3M · modeled $23.4M (est)Edison Oncology Holding Corp (this company) Raised $882K · modeled $8.8M (est)Edison Oncology Holding Corp
CompanyStageRaised · realValue · estvs peer med.
Elion Oncology, Inc.Pre-Seed$1.0M$47.3M3.54×
Cyclone Therapeutics, Inc.Pre-Seed$800K$37.8M2.83×
Sonnet Biotherapeutics, Inc.Pre-Seed$750K$35.5M2.66×
Fastball Capital Group, LlcPre-Seed$750K$35.5M2.66×
TamRx, LLCPre-Seed$700K$33.1M2.48×
Veana Therapeutics, Inc.Pre-Seed$1.4M$32.9M2.46×
Ariz Precision Medicine, Inc.Pre-Seed$685K$32.4M2.43×
Vascarta Inc.Pre-Seed$649K$28.1M2.10×
Enfuego Therapeutics, Inc.Pre-Seed$1.0M$27.0M2.02×
Sincerus Pharmaceuticals IncPre-Seed$506K$23.9M1.79×
Neurodon CorpPre-Seed$500K$23.7M1.77×
Elite Pharmaceuticals Inc /Nv/Pre-Seed$3.3M$23.4M1.75×
Edison Oncology Holding Corp this companyPre-Seed$882K$8.8M0.66×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$632K2018-10-05$3.5M$29.9M90%
Pre-Seed$250K2020-12-30$1.4M$8.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$632K2018-10-05
    • First recorded raise — entered as Pre-Seed.
    • 16 investors on this round.
  2. Pre-Seed$250K2020-12-30
    • Raised again after 27 mo — slower than the ~13 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 7 investors on this round.
Intelligence
2023 ~Q1
Modeled next raise · ~27mo cadence
$250K
Modeled next size est.range $250K$400K
0.4×
Last step-up
$395K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brett Nesland2 other2018-10
Jeffrey A. Bacha1 other2020-12
Jeffrey Bacha1 other2018-10
Sean Martin1 other2018-10
Registry & provenance

Edison Oncology Holding Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1753347
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Oncoquest Pharma Usa, IncPharmaceuticalsPre-Seed$870K$10.5Msame sector · same stage
Ionia Pharmacy, LLCPharmaceuticalsPre-Seed$900K$7.1Msame sector · same stage
Macrotope, Inc.PharmaceuticalsPre-Seed$900K$1.1Msame sector · same stage
Ascalon International, Inc.PharmaceuticalsPre-Seed$905K$4.7Msame sector · same stage
PRG FlowChem, Inc.PharmaceuticalsPre-Seed$825K$2.5Msame sector · same stage
Tetra Discovery Partners LlcPharmaceuticalsPre-Seed$945K$13.2Msame sector · same stage
Cearna, Inc.PharmaceuticalsPre-Seed$806K$4.7Msame sector · same stage
Primus Therapeutics Inc.PharmaceuticalsPre-Seed$800K$14.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
EvolveImmune Therapeutics Holding Company, LLCBiotechnologySeries B$124.9M78%
IntelGenx Technologies Corp.PharmaceuticalsSeed$7.1M78%
PharmID, Inc.PharmaceuticalsSeries A$154.9M78%
Oncology Institute, Inc.Hospitals and PhysiciansSeries D+$144.8M78%
Oncopia Therapeutics, LLCBiotechnologySeries A$54.2M78%
Med-Tech Investments Group, LLCPharmaceuticalsSeed$98.9M78%
Response Pharmaceuticals, Inc.PharmaceuticalsSeries A$20.5M78%
Evogene Ltd.PharmaceuticalsSeries A$8.5M78%
Frequently asked
How much funding has Edison Oncology Holding Corp raised?
Edison Oncology Holding Corp has raised approximately $882K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Edison Oncology Holding Corp's estimated valuation?
Provath's modeled valuation for Edison Oncology Holding Corp is approximately $8.8M (modeled range $140K–$86.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Edison Oncology Holding Corp at?
Edison Oncology Holding Corp's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Dec 30.
What does Edison Oncology Holding Corp do and where is it based?
Edison Oncology Holding Corp operates in the Pharmaceuticals sector, based in MENLO PARK.
Explore related

See where Edison Oncology Holding Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Edison Oncology Holding Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.